# OnCo record bridgebio-oncology-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/bridgebio-oncology-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "bridgebio-oncology-therapeutics" ;
  schema:name "BridgeBio Oncology Therapeutics"@en ;
  schema:alternateName "QED Therapeutics, a BridgeBio company"@en, "QED Therapeutics"@en ;
  schema:description "BridgeBio Oncology Therapeutics (BBOT) makes pills against the KRAS cancer protein and a drug that stops KRAS from switching on a second growth signal called PI3K-alpha. All three drugs are in early human trials."@en ;
  schema:url <https://onco.cc/companies/bridgebio-oncology-therapeutics/>, <https://bbotx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://bbotx.com/>, <https://bbotx.com/pipeline/>, <https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex99-4_bridge.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/pik3ca/> ;
  onco:drugs <https://onco.cc/drugs/infigratinib/> .